Nestle sells peanut allergen Palforzia

05-Sep-2023 - (dpa-AFX) Food giant Nestlé has found a buyer for its peanut allergy drug Palforzia. The business, which Nestlé put in the shop window last November as part of a strategic review, will go to Stallergenes Greer, a biopharma company headquartered in London. Under the agreement, Stallergenes Greer ...

Vantage Nutrition LLC acquires AquaCap from Nestlé Health Science

Vantage Nutrition’s nutraceutical offering expands into North America

08-Dec-2022 - Vantage Nutrition, an ACG Group company, announced on 5th December 2022 that it has acquired Philadelphia-based ‘AquaCap’ – an asset of Nestlé Health Science. AquaCap is a leading contract manufacturer of liquid-filled capsules within the nutritional supplement industry in the United States. Its ...

Enterome and Nestlé Health Science launch new diagnostics company

11-Jul-2017 - ENTEROME SA and Nestlé Health Science, announce the joint creation of Microbiome Diagnostics Partners (MDP). This company will bring together complementary, world-leading platforms and capabilities enabling the discovery and development of innovative diagnostics through to commercialization in ...

BioGaia enters new agreement with Nestlé

13-Mar-2014 - In February 2012 BioGaia sold the rights for the use of Lactobacillus reuteri Protectis in infant formula to Nestle for the remainder of the patent lifetime. BioGaia received EUR 40 million up-front and a commitment to a further EUR 10.8 million during the period 2014 to 2017 upon achievement of ...

BioGaia receives the first instalment of additional payment from Nestlé

19-Feb-2014 - In February 2012 BioGaia signed several new agreements with Nestlé including the acquisition of the license to use BioGaia’s Lactobacillus reuteri Protectis in infant formula during the remaining term of the patent. The purchase price was EUR 50.8 million, of which EUR 40.0 million (SEK 356 ...

Chi-Med and Nestlé Health Science establish Joint Venture

30-Nov-2012 - Nestlé Health Science SA, a fully-owned subsidiary of Nestlé SA, and Chi-Med, announced that they have agreed to form a 50/50 joint venture to be named Nutrition Science Partners Limited (“NSP”).The purpose of NSP is to research, develop, manufacture and market worldwide novel medicines and ...

Nestlé Health Science S.A. and Nestlé Institute of Health Sciences established to target new opportunity between food and pharma

06-Oct-2010 - Nestlé announced the creation of Nestlé Health Science S.A. and the Nestlé Institute of Health Sciences to pioneer a new industry between food and pharma. These two separate organisations will allow Nestlé to develop the innovative area of personalised health science nutrition to prevent and ...

New evidence that dark chocolate helps ease emotional stress

16-Nov-2009 - The "chocolate cure" for emotional stress is getting new support from a clinical trial published in the Journal of Proteome Research. It found that eating about an ounce and a half of dark chocolate a day for two weeks reduced levels of stress hormones in the bodies of people feeling highly ...

Novartis completes acquisition of 25% stake in Alcon from Nestlé for approximately US$ 10.4 billion in cash

First step toward majority ownership of the world leader in eye care

09-Jul-2008 - Novartis has acquired a 25% stake in Alcon Inc. as part of a definitive agreement with Nestlé S.A. reached in April 2008 that provides the right to acquire majority ownership of the world leader in eye care in two steps. The first step was completed on July 7 when Novartis purchased the Alcon ...

Phosphagenics and Nestlé Nutrition extend option agreement

Phospha E® clinical program to progress as planned

10-Jul-2007 - Phosphagenics Limited announced that it has, by mutual consent, extended the period in which a commercial agreement is to be concluded with Nestlé Nutrition. In January 2007, Nestlé exercised its option to negotiate (on an exclusive basis) a commercial agreement with Phosphagenics for the use of ...